ASGCT 2026
|
5.15.26
End-to-end device compatibility and in-use stability assessment of an AAV gene therapy delivered by convection-enhanced delivery
ASGCT 2026
|
5.15.26
MRI-Guided Convection-Enhanced Delivery of an AAV-hIFNβ Vector Achieves Targeted Brain Retention and Durable Transgene Expression in a Large-Animal Model
Molecular Therapy Oncology
|
5.4.26
AAV immuno-gene therapy platform delivering vectorized cytokines defines a new modality for high-grade glioma treatment
